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Tail-anchor sequenceThe localization and control of Bcl-2 proteins on mitochondria is essential for the intrinsic pathway of
apoptosis. Anti-apoptotic Bcl-2 proteins reside on the outer mitochondrial membrane (OMM) and prevent
apoptosis by inhibiting the activation of the pro-apoptotic family members Bax and Bak. The Bcl-2 subfamily
of BH3-only proteins can either inhibit the anti-apoptotic proteins or directly activate Bax or Bak. How these
proteins interact with each other, the mitochondrial surface and within the OMM are complex processes we
are only beginning to understand. However, these interactions are fundamental for the transduction of
apoptotic signals to mitochondria and the subsequent release of caspase activating factors into the cytosol. In
this review we will discuss our knowledge of how Bcl-2 proteins are directed to mitochondria in the ﬁrst
place, a crucial but poorly understood aspect of their regulation. This article is part of a Special Issue entitled
Mitochondria: the deadly organelle.micellar concentration; CtTA,
Green ﬂuorescent protein; GIP,
MTCH2, Mitochondrial carrier
permeabilization; OMM, Outer
brane; TOM, Transporter outer
al recognition particle; VDAC,
ondria: the deadly organelle.
(J. Lindsay).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction: The mitochondria as an essential point for
apoptosis regulation
Apoptosis is fundamental to multi-cellular organisms during both
development and homeostasis. This process of controlled cell suicide
ensures that cells grow and divide only when in the correct context
and are removed when they become irreparably damaged or surplus
to requirements. The absence of survival signals or cellular damage
activates a highly ordered and controlled cell suicide program, which
provides the most efﬁcient and least damaging way to remove
unwanted cells. The balance between survival and apoptotic signals
must be tightly controlled, and the failure of these controls on
apoptosis contributes to diseases such as cancer [1].
Apoptosis can be initiated by extrinsic factors, such as ligands for
cell surface death receptors (not within the scope of this review) or
intrinsically by responding to damage and stress [2]. In both cases,
classical apoptosis results in the activation of cysteinyl aspartyl
proteases (caspases) that then rapidly dismantle the cell [3]. Caspasesare present as inactive pro-enzymes in healthy cells, poised to drive
cellular destruction upon receipt of an activating signal. This
destruction is not passive through to the degradation of cellular
proteins, but rather is driven by signaling events where many caspase
substrates are themselves activated by cleavage [4].
In most cases, cells undergo apoptosis via engagement of the
intrinsic pathway, the regulation of which is centered at the mitochon-
dria. This has as its critical point of no return mitochondrial outer
membrane permeabilization (MOMP), a sudden and dramatic event
resulting in the release of soluble factors from the intermembrane space
[5]. Thekey factors released, cytochrome c andSMAC/DIABLO, cooperate
with cytosolic factors to activate the caspases. The Bcl-2 family proteins
are the essential regulators of MOMP, and the correct targeting of the
Bcl-2 family to mitochondria is critical for apoptosis [6]. The purpose of
this review is to discuss the mechanisms by which mitochondrial
targeting of Bcl-2 proteins are achieved.
2. Bcl-2 protein function—The accepted models of cell death
activation
The Bcl-2 family proteins are critical regulators of apoptosis, and
their primary site of action is on the outer mitochondrial membrane
(OMM). This is not to say that mitochondria are the only site of action
of Bcl-2 proteins, and the literature has examples of other functions,
such as on the ER for example [7]. Bcl-2 proteins can be classiﬁed as
either pro-apoptotic or anti-apoptotic [6]. Initial characterization of
Bcl-2 proteins, before any structural information became available,
identiﬁed a number of regions of sequence homology between them
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sequence homology conveniently mapped onto the functional classiﬁ-
cation of Bcl-2 proteins, supporting the supposition that they did indeed
represent structural domainswithin thesemolecules. The anti-apoptotic
proteins, including Bcl-2, Bcl-XL, Bcl-w andMcl-1 contain BHdomains1–
4. These anti-apoptotic proteins are generally found on the OMM,where
they function to inhibit the pro-apoptotic Bcl-2 proteins. The pro-
apoptotic Bcl-2 proteins are divided into themulti-domain effectors Bax,
Bak and Bok (containing BH domains 1–3), or BH3-only proteins, which
contain only the BH3 domain. However, care has to be taken when
describing these regions of sequence homology as “domains”. A protein
domain is a conserved, 3-dimensional structure that is stably folded
independent of the rest of the protein and can exist and evolve in
isolation. The Bcl-2 family are all small, globular proteins. The 3-
dimensional structures known for Bcl-2 proteins, including Bax, Bcl-
w and Bcl-XL suggest that the BH “domains” are not independently
folded structural units, but instead are integral parts of theBcl-2 proteins
compact 3-dimensional structure [8–10]. However, two regions that do
appear to have distinct structural and functional identities are the BH3
domain and the C-terminal tail anchor. The basis of Bcl-2 protein
function in apoptosis is largely centered on these two regions.
The multi-domain pro-apoptotic proteins Bax and Bak are thought
to promote MOMP by oligomerizing to form pores within the OMM
[11]. The BH3-only proteins, such as Bid, Bim and Bad, act as either
direct activators of pro-apoptotic Bax and Bak, or as de-repressors of
anti-apoptotic Bcl-2 and Bcl-XL [12,13]. Two conﬂicting models of
how this occurs have been presented, reviewed in [14]. The ﬁrstFig. 1. Localization of Bcl-2 family proteins. In normal healthy cells Bcl-2 proteins are found
proteins, such as Bcl-2, Bcl-XL, Bcl-w and Mcl-1, are found on the OMM where they act to inh
Bak also on the OMM. Bcl-2 is always integrally inserted into the OMM, whereas the other an
Bak is constitutively found on the OMMwhereas Bax is predominantly found as an inactivem
to form homo- and hetero-dimers with Bak. Some BH3-only proteins (Bim, Puma and Nox
following apoptotic signals, whereas others are post-translationally modiﬁed to control the
directly activate the pro-apoptotic proteins Bax or Bak or inhibit the anti-apoptotic membeproposes that Bax and Bak are constantly held in check by the anti-
apoptotic activity of the Bcl-2 like proteins. This repression is relieved
by activated BH3-proteins, releasing Bax and Bak to drive MOMP. The
alternative view is that some BH3-proteins (Bid, Bim and Puma)
directly bind to and activate Bax and Bak, but that in a healthy cell
their exposed BH3-domains bind to and are sequestered by anti-
apoptotic Bcl-2 proteins. Bid has recently been found to be
structurally and phylogenetically closer to multi-domain Bcl-2
proteins [6], but in this review we will maintain its historical
deﬁnition as a classical BH3-only protein. The other BH3-proteins,
such as Bad, compete for binding to the anti-apoptotic proteins, and
displace Bid, Bim and Puma to allow them to activate Bax. These
models share the common feature that the key interaction proposed is
between the BH3-domain of the BH3-only proteins and the multi-
domain proteins.
What is less clear is how survival or death signals lead to activation
of the Bcl-2 family speciﬁcally on themitochondria. In normal healthy
cells, most anti-apoptotic multi-domain Bcl-2 family members are
constitutively found in the OMM or the endoplasmic reticulum (Fig. 1,
left). The multi-domain pro-apoptotic protein Bak is constitutively
localized to the OMM. Conversely, Bax is predominantly found in the
cytosol and is recruited to the OMM upon receipt of an apoptotic
signal [15,16]. It should be noted, however, that Bax is not exclusively
cytosolic prior to apoptosis, and that detectable amounts can be seen
on mitochondria in healthy cells. Furthermore, Bax translocation to
mitochondria does not commit a cell to undergo MOMP. Inducing Bax
translocation, by either mutating amino acids within its targetingboth in the cytoplasm and on the OMM. It has been proposed that the anti-apoptotic
ibit apoptosis through interaction and inhibition of the pro-apoptotic proteins Bax and
ti-apoptotic members can be soluble, loosely attached or integrated into the membrane.
onomer in the cytoplasm, which then translocates to themitochondria in apoptotic cells
a) are expressed at low levels in healthy cells and are transcriptionally up-regulated
ir localization (Bad, Bim, Bid). Once at the mitochondria the BH3-only proteins either
rs such as Bcl-2 or Bcl-XL.
Fig. 2. Bcl-2 family tail anchor sequences. Comparison of putative c-terminal tail anchor
sequences inmulti-domain Bcl-2 familymembers. The underlined Z represents the stop
codon in the coding sequence, highlighting that the C-terminal portion of the protein
within the mitochondria is extremely short (between 1 and 6 amino acids). Most
contain a readily identiﬁable transmembrane domain (TMD), apart fromBok and Bcl-A1,
which contain polar amino acids within the TMD. These might be predicted to prevent
membrane insertion, but to date no data is available for the function of these putative tail
anchor sequences. As can be seen, there is considerable variation in the TMD region
(both in terms of length and hydrophobicity) and theﬂanking sequences. Bcl-XL and Bak
have the most polar ﬂanking sequences (polar amino acids are highlighted in red). The
regulatory proline in Bax (P168) is highlighted in blue. Although this Bax CtTA does not
have any N-terminal charged residues, it has been veriﬁed as a functional mitochondrial
targeting sequence (see references in the text).
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mitochondrial associated Bax without MOMP.
During apoptosis Bax and Bak both undergo conformational changes
associated with MOMP [16,19]. Bax must undergo both conformational
change and targeting to the OMM to activate apoptosis (Fig. 1, right).
Members of the BH3-only proteins also target to the mitochondria to
activate Bax or Bak or inhibit Bcl-2 or Bcl-XL. These proteins are either
transcriptionally induced (e.g. Bim, PUMA and Noxa) and/or post-
translationally modiﬁed (e.g. Bim, Bid, Bad) prior to translocation [20].
For example Bad is phosphorylated by survival signals such as the PI3K/
Akt pathway, which promotes binding to 14–3–3 scaffold proteins,
sequestering it in the cytoplasm [21,22]. Loss of survival signal leads to
Bad dephosphorylation and dissociation form 14–3–3, where it can
translocate to the mitochondria and interact with Bcl-XL. The BH3-only
protein Bid is inactive in the cytosol in healthy cells and is predominantly
regulated by cleavage by caspase 8 [23]. Following apoptotic signals, Bid
or tBid translocates to the mitochondria and interacts with Bax/Bak on
the OMM to promote cytochrome c release and apoptosis.
However, none of these models fully explains how these proteins
get to the correct membrane in the ﬁrst place. Although proper
targeting of Bcl-2 family proteins to mitochondria is essential for their
function, very little is actually known regarding how this is achieved.
Because this represents a critical point in their regulation, it warrants
some consideration.
3. Tail anchor mediated targeting of multi-domain Bcl-2 proteins
to the OMM
3.1. Bcl-2 protein tail anchors
Out of the estimated 1000+ proteins found in mitochondria, only
13 are encoded for by the mitochondrial genome [24,25]. Thus, the
vast majority of mitochondrial proteins, including the Bcl-2 family,
need to be post-translationally targeted to the correct mitochondrial
compartment [26,27]. A number of different types of mitochondrial
addressing sequence are known that can achieve this, including N-
terminal presequences, internal membrane spanning sequences, and
C-terminal tail anchors. Each utilizes distinct mechanisms for
mitochondrial import, some of which are better understood than
others. For example, much is known about the mechanisms by which
mitochondrial proteins containing an N-terminal presequence are
imported through the general import pore (GIP), consisting of the
TOM and TIM translocase complexes [28]. The TOM complex acts as
both a receptor and the import machinery for proteins with N-
terminal presequences. These are unfolded, translocated through the
pore to traverse the membrane, and subsequently refolded following
arrival at the correct mitochondrial compartment. The nature of the
N-terminal presequence plays a role in the ﬁnal destination.
C-terminal tail anchors are another class of targeting sequence, but
are not restricted to mitochondrial proteins [29]. These sequences target
to other organelles as well, notably the endoplasmic reticulum (ER), the
organellewhere thismechanismhas beenmost extensively studied [30].
UnlikeN-terminal targeting sequences, aC-terminal tail anchor sequence
(CtTA) requires the protein to have completed translation before
targeting can occur. Tail-anchored proteins do not show exact sequence
conservation in the tail region, but instead share some common
characteristics that determine CtTA function. There is a hydrophobic
transmembrane domain (TMD) of approximately 20 amino acids,
enough to span the target membrane once, ﬂanked by charged amino
acids. Variations in hydrophobicity and the ﬂanking sequence contribute
to targeting speciﬁcity [31–33]. All CtTA proteins, whatever their
subcellular localization, arepositioned such that theproteinsN-terminus,
containing the proteins functional domain, is cytosolic. The C-terminus is
usually very short, usually only a few amino acids, and is always within
the lumen of the target organelle. The addition of a large protein domain
C-terminal to a CtTA blocks targeting and insertion [34].Almost all the multi-domain Bcl-2 proteins, both pro- and anti-
apoptotic, contain a functional CtTA. The multi-domain Bcl-2 proteins
Bak, Bcl-2, Bcl-XL, Bcl-w and Mcl-1 have C-terminal sequences that
contain all the classical features of a CtTA [34–38] (Fig. 2). In most
cases, the CtTA of each has been validated experimentally. Deletion of
the CtTA domain prevents targeting, and attachment of the CtTA to a
heterologous protein (such as GFP) directs targeting, two key tests to
show a putative CtTA is functional [34,39–41]. Bcl-2 has ﬂanking
sequences that are not as polar as in Bcl-XL, and this explains its
distribution between both the ER and the mitochondria. Bcl-XL, in
contrast, targets mitochondria. Manipulation of the TMD ﬂanking
sequences of either Bcl-2 or Bcl-XL altered their targeting speciﬁcity
[32].
Not all multi-domain Bcl-2 proteins have CtTA sequences that ﬁt
the classical criteria. Bax is unusual in that its Ct-TA is not preceded by
any polar amino acids (Fig. 2). From this, some studies suggested that
Bax does not have a functional Ct-TA, and is instead targeted to
mitochondria via an N-terminal presequence [42,43]. The Bax N-
terminus was proposed to direct Bax to the GIP through an interaction
with TOM22, a model that might explain the N-terminal conforma-
tional change in Bax associatedwith apoptosis [44]. However, the data
supporting a role for TOM proteins in Bax targeting is conﬂicting, and
will be discussed further below. Furthermore, a number of other
studies have presented convincing evidence that Bax does indeed
have a functional CtTA, which is both necessary and sufﬁcient for
mitochondrial targeting [34,45]. Bax is unusual, however, in that its
tail anchor does not constitutively target. Instead, Bax is predom-
inantly cytosolic until the cell receives an apoptotic stimulus
[17,18,46]. The differences between the Bax and other mitochondrial
CtTA sequences appear to be important for this regulated insertion of
Bax compared with the constitutive insertion of other proteins. The
region where Bcl-XL has acidic residues N-terminal to the TMD is
replaced in Bax by a proline at residue 168. In the NMR structure of
human Bax, the trans conformation of this proline enables the CtTA to
be folded back along a groove on the surface of Bax, explaining why
targeting is not constitutive [8]. Experimental manipulation of Pro168
or sequences within the TMD itself, result in either constitutively
targeted Bax or versions that neither target nor induce apoptosis
[17,45]. However, as mentioned earlier, expression of constitutively
targeted Bax does not result in uncontrolled cell death and instead it
now resembles Bak in function [17]. Thus, once on the OMM, Bax is
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unusual CtTA remains unclear.
How the Bax CtTA is exposed to direct targeting is largely
speculative, as there is no structure available for the membrane-
inserted conformation. However, the regulation is not intrinsic to the
Bax CtTA itself or its unusual N-terminal ﬂanking sequence, and does
require the context of the rest of Bax. The Bax CtTA, including Pro168,
constitutively targets GFP to mitochondria [34]. The current model is
that binding of activated BH3-only proteins induces the conforma-
tional exposure of the Bax CtTA. The Bim BH3 helix has been shown to
bind on the opposite face of Bax, and that this might loosen the
association of the CtTA to allow targeting [47]. However, activated Bid
has been shown to only bind to Bax once both Bid and Bax have
already associated with a membrane, suggesting that targeting must
precede the BH3-domain interaction [48]. It is not clear if Bim and Bid
activate Bax through different mechanisms, or if the use of isolated
BH3-peptides alters the way they interact with multi-domain Bcl-2
proteins.
Bok, the third mammalian pro-apoptotic multi-domain protein, is
less understood, has a restricted expression and may be associated
with placental pathologies [49,50]. Bok is variously described as
having a nuclear or mitochondrial distribution. The C-terminus of Bok
does not ﬁt the consensus for a functional CtTA, as it contains lysine
and arginine residues within what should be the hydrophobic TMD
(Fig. 2). This would be predicted to prevent membrane insertion, but
to date there is no published data on the ability of the Bok C-terminus
to target any organelle. Whether or not Bok has a functional CtTA
remains to be determined.
3.2. Mechanisms of tail anchor import
Given that the vast majority of mitochondrial proteins are
imported from the cytosol, it should be no surprise that the
mechanisms for their import have been an intensive area of study.
However, although a lot is known about mitochondrial import of N-
terminally tagged proteins, which occurs via the GIP, much less is
known about how mitochondrial CtTA proteins are imported and
what, if any, co-factors are required. Fortunately, rather more is
known about ER CtTA import, and from this some general concepts
can be extracted that may apply to mitochondria. At least three
distinct pathways have been characterized at a molecular level for ER
CtTA import [30]. These can involve both chaperones and receptors,
and some are dependent upon nucleotide hydrolysis. The functions of
some chaperones, like SRP, appear to involve masking the more
hydrophobic CtTAs as they emerges from the ribosome, preventing
aggregation, and then interacting with a receptor on the ER
membrane. There is also evidence of a further protein required for
driving the membrane insertion of the TMD. Another chaperone,
involving Hsp40 and Hsc70, appears to target less hydrophobic CtTA
proteins, such as cytochrome b5, and these do not require proteins
present on the ER for membrane integration [51]. Thus, the level of
hydrophobicity of the CtTA itself contributes to the requirement for
different chaperones. Moderately hydrophobic TMDs, such as in
cytochrome b5, do not require chaperones to insert into membranes
following in vitro translation, whereas more hydrophobic sequences,
such as that found in synaptobrevin, do. However, the key ﬁnding is
that there is no universal mechanism for the biogenesis of CtTA
proteins on the ER. It would not, therefore, be surprising if multiple
mechanisms were seen for mitochondrial CtTA proteins as well.
Indeed, it has been shown that the CtTA proteins of the TOM complex
are targeted by a mechanism distinct from CtTA proteins that are
dispersed throughout the OMM [52].
So what is known about factors required for targeting mitochon-
drial CtTA sequences, and speciﬁcally Bcl-2 proteins? The published
data here are often conﬂicting, but there is evidence that other
mitochondrial proteins do contribute to Bcl-2 protein targeting. Aninteraction between Bcl-2 and TOM-20 has been suggested to be
required for its mitochondrial insertion in yeast [53]. However, other
studies showed that trypsin treatment of mitochondria did not block
Bcl-2 association and insertion into the OMM [36]. Bcl-2 has a
moderately hydrophobic CtTA and, like cytochrome b5, may well be
able to undergo unassisted membrane insertion. A recent study has
shown that the targeting of Bak and Bcl-XL to mitochondria is TOM
independent [54]. The cytoplasmic portion of the protein may also be
important, and the requirement for a mitochondrial protein for
targeting and insertion was dependent on the presence of the intact,
full-length Bak. The Bak CtTA alone was able to target and insert into
mitochondria in which the voltage dependent anion channel, VDAC2,
had been depleted. However, in the context of full-length Bak, loss of
VDAC2 prevented targeting and insertion. VDAC2 has been shown in
other studies to be able to interact with Bak, with a role in preventing
Bak activation [55,56]. Another study has also indicated a role for
VDAC in Bak mitochondrial targeting, suggesting that biogenesis of at
least some Bcl-2 proteins requires a mitochondrial receptor [57].
Whether or not Bax requires a mitochondrial receptor is also
unclear, with a number of studies indicating that TOM proteins may
play a role [44,58]. Again, if we compare with ER-CtTA import, we see
that SRP is best known as a mediator of classical signal-sequence
driven, co-translational import [30]. Thus, it is not unprecedented for
components of an N-terminal import sequence pathway to direct the
insertion of CtTA containing proteins as well. Thus, it cannot be ruled
out that components of the GIP can act as receptors for Bcl-2 proteins.
However, the published data on Bax targeting and the GIP are
confusing and contradictory. Direct binding between Bax and
TOM22 has been shown [44]. However, studies in yeast have provided
conﬂicting data. Using a temperature sensitive yeast mutant, Ott et al.
demonstrated a requirement for the TOM40 channel for tBid induced
Baxmitochondrialmembrane insertion and cytochrome c release [58].
However, in a similar study not only was TOM40 not required for Bax
induced cytochrome c release, but the three TOM complex receptors,
TOM20, TOM22 and TOM70were also dispensable [59]. Bax can insert
into and permeabilize protein-free liposomes prepared from extracted
mitochondrial lipids [60]. This would imply that Bax does not
absolutely require a receptor protein for membrane insertion.
However, whether this is the case in vivo, or if different multi-domain
Bcl-2 proteins use different mechanisms, has yet to be clariﬁed.
A number of studies have suggested that cytoplasmic Bax may
interact with chaperones, such as 14–3–3 proteins [61,62]. These
interactions have been proposed to control its distribution by
maintaining Bax in the cytoplasm in healthy cells. Some ER CtTA
proteins do interact with chaperones in the cytoplasm, as discussed
above. These chaperones both mask the hydrophobic TMD to
maintain its integration competence and to direct interactions with
receptors on the target membrane. However, the structure of Bax
suggests that it can act as a chaperone for its own CtTA, which is
folded back along the surface groove [8]. Whether or not other Bcl-2
family proteins interact with chaperones is not completely clear. It has
been suggested that cytoplasmic proteins may not be required for Bcl-
XL import, but were required for full-length Bak [54]. At present our
knowledge of Bcl-2 protein targeting to mitochondria is still
incomplete.
4. Non-tail anchor mediated interactions with mitochondria
Most BH3-only proteins present a different set of issues with
regard to mitochondrial targeting. Many studies have focused on the
interactions of these via their BH3-domains, and the contribution of
the rest of the molecule is poorly understood in most cases. However,
in those cases where it has been examined, it is clear that BH3-only
proteins contain speciﬁc targeting regions that are vital for their
normal regulation. Fundamentally, mitochondrial targeting of Bcl-2
family proteins may depend upon three types of interactions: 1) with
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mitochondria; 3) with proteins of other families, including enzymes
that produce post-translational modiﬁcations. Intriguingly, the ﬁrst
two types of interactions can be mimicked in vitro by certain
detergents. Therefore, we will ﬁrst survey how detergents inﬂuence
the oligomerization and reciprocal interaction of Bcl-2 proteins.
4.1. Bcl-2 proteins are sticky and react with detergents
One basic fact underlies both the process of activation and that of
mitochondrial targeting: Bcl-2 proteins with multiple BH domains are
rather sticky and therefore can dynamically associate with small
hydrophobic molecules like detergents and lipids. Besides the
hydrophobic C-terminal tail already discussed here, Bcl-2 proteins
possess a prominent hydrophobic groove at their surface, in which the
BH3 domain of other Bcl-2 proteins can ﬁt. This property has provided
a model for building potent antagonist drugs such as ABT-737 [63,64].
The structural design of these drugs revealed that the surface groove
of Bcl-XL is likely to accommodate a variety of hydrophobic molecules,
besides the amphipatic alpha-helix forming the BH3 domain of BH3-
only proteins such as Bad [64]. Indeed, the same groove of Bcl-XL has
been reported to bind diverse detergents at concentrations in which
they are monomeric in solution [65].
Above their critical micellar concentration (CMC), the same
detergents produce large conformational changes in Bcl-XL [65] as
well as Bax [8], due to complex interactionswith themicelles that drive
protein oligomerization [66–69]. Because inmost instances cell extracts
have been made with concentrations of non-ionic detergents (such as
Triton-X-100) that are well above their CMC, spurious homo- and
hetero-oligomerization of Bcl-2 proteins have been detected solely
due to the multimeric effect of interacting with detergent micelles
[68]. This problem is sometimes overlooked, especially in recent
literature. Considering also the lack of speciﬁc reviews on the
interactions between Bcl-2 proteins and detergents, we need to stress
their important implications, in experimental studies as well as in the
understanding of the activation and membrane interaction of Bax.
Detergents are amphipatic molecules that mimic natural lipids, in
particular the mono-acyl derivatives of phospholipids such as
lysophosphatidyl-glycerol (LPG). They can be ionic and negatively
charged like natural LPG, e.g. SDS, or non-ionic, as most detergents
used in cell biology (Triton, Tween, octyl-glucoside etc.). There also
are a few detergents with zwitterionic properties, i.e. having both
positive and negative charges. Perhaps the most popular of these
detergents is CHAPS, a cholesterol derivative, which has been
considered the only detergent capable of maintaining Bax monomeric
in micelles [66,69]. However, CHAPS may not be ideal for extracting
mitochondrial Bax in its native quaternary structure [70].
Bax interactions with detergents have received most attention.
However, it remains unclear whether the protein is truly oligomeric in
detergent micelles or is merely embedded in multiple copies within
the same micelles, without forming directly bound oligomers. Indeed,
it has been recently claimed that Bax (without its C-terminal helix)
may be monomeric within the micelles of non-ionic detergents [71].
The intriguing proposal, which would not explain the established
evidence of detergent-induced Bax oligomerization [66], has been
subsequently criticized [72] with reference, once more, to the
importance of the C-terminal helix of Bax. When the C-terminal
helix of Bax is missing, the surface groove is free and may be ﬁlled
with detergent molecules after artiﬁcial activation with micelles of
non-ionic detergents, as documented with truncated Bcl-XL [65].
Perhaps the C-terminal helix of Bax can effectively work like a
detergent in driving the conformational changes associated with
activation and then binding to the OMM. In this respect, the
interactions of Bcl-2 proteins with detergents may mimic protein–
protein interactions, besides their most obvious mimic of protein–
lipid interactions.4.2. Mitochondrial lipids: Cardiolipin
The interaction of Bid with mitochondrial lipids has provided new
insights to explain how Bcl-2 proteins target mitochondria and then
elicit MOMP [98]. Although joined at contact sites, the two
membranes of mitochondria are very different in their lipid
composition. While the outer membrane is rather similar to those of
the ER compartment, with which it is often contiguous, the inner
membrane contains the smallest complement of glycolipids and
cholesterol, as well as the highest concentration of the glycerol-based
phospholipid cardiolipin of any intracellular membrane. Cardiolipin is
indeed synthesized and re-modeled within mitochondria and is
present in discrete amounts also on the outer surface. It is this small
pool of surface-exposed cardiolipin that can justify the role that
cardiolipin has been shown to play in the integrated pro-apoptotic
action of Bid and Bax [73]. Here we discuss cardiolipin only in the
context of mitochondrial targeting of Bcl-2 proteins. Except for the
subgroup of BNIP3, BH3-only proteins do not contain a tail-anchor
sequence for insertion into mitochondrial membranes but may
contain C-terminal lipid-binding motifs as Bid does [74–80]. For
example, the C-terminal region of Bad contains two lipid binding
motifs required for binding to negatively charged lipids, such as
cardiolipin, and for targeting to the mitochondria. This binding of Bad
to membranes was shown to also facilitate the translocation of Bcl-XL
to membranes. The targeting of Bcl-XL to mitochondria and its
insertion into the OMMwas inhibited by lipid binding mutants of Bad
that could still interact with Bcl-XL but not membranes.
However, hard evidence for a direct interaction with cardiolipin
(and its metabolites) is available only for Bid, and especially for its
protease-cleaved form tBid. The interaction of tBid with cardiolipin
has been shown to involve helix αH6 of the protein, in particular its
lysines 157 and 158 [76]. However, recent work in our lab has shown
that although this interaction is important for Bid:lipid binding in
vitro, mutation of one of these residues did not affect the ability of Bid
or tBid to localize in mitochondria and induce cytochrome c release
and apoptosis in vivo [81]. Multiple interpretations of these results are
possible [81] but it is probable that the interaction of Bid with
cardiolipin has three-dimensional connotations that alterations in
individual amino acids may not disrupt. Although some studies have
reported that a lack of cardiolipin has no effect on cytochrome c
release or targeting of tBid to mitochondria [58,82–84], recent
evidence has established that cardiolipin does have a role in
promoting MOMP (see review by Crimi and Degli Esposti in this
special issue).
In essence, it seems increasingly likely that the interactions of Bid
(and other Bcl-2 proteins) with cardiolipin documented in vitro reﬂect
the existence of proteo-lipid domains that are involved in vivo in the
process of MOMP. Speciﬁc proteins may therefore be either part of
these domains or modulate the insertion of Bcl-2 proteins into them.
4.3. Interaction with other proteins
In the context of protein–protein interactions within the Bcl-2
family, the BH3 domain has received the most attention. However
there is clear evidence that although the BH3 domain is required for
the apoptotic function of these proteins it is not essential for targeting
[74,79,85]. Bid translocates to mitochondria following apoptotic
stimuli as either the full-length protein or caspase cleaved p15Bid
[85–87]. However, the targeting of Bid to the mitochondria is
independent of the BH3 domain [85,88]. A truncated form of tBid,
lacking the BH3 domain, constitutively targets to mitochondria but
does not kill the cells [81]. This suggests that targeting of Bid to
mitochondria does not require interaction with multi-domain Bcl-2
proteins. Bid may, however, bind to other proteins on the mitochon-
dria that speciﬁcally regulate its targeting. Mitochondrial carrier
homologue 2 (Mtch2) is a recently characterized OMM protein that
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knockout mice die at embryonic day E7.5 mainly due to multiple
defects in gastrulation [89]. Conditional knockout MEFs show
decreased sensitivity to tBid-induced apoptosis due to decreased
recruitment of tBid to the mitochondria, and subsequent Bax
activation and cytochrome c release. This decreased tBid recruitment
was also shown in vivo in puriﬁed intact liver mitochondria prepared
from liver-speciﬁc knockout mice. These results suggest a direct link
between the levels of an OMM protein, Mtch2, and the level of
recruitment of tBid to the OMM. Mtch2 deﬁciency did not affect the
lipid composition of the OMM [89], suggesting a direct protein:protein
recruitment model. However, tBid recruitment is not completely
blocked suggesting an additional level of control, such as another
protein or the lipid composition of the OMM as discussed above.
Bad is perhaps the best understood BH3-protein in terms of its
interactions with other proteins, and demonstrates a remarkable
complexity. The interactions of Bcl-2 proteins with other proteins
encompass the issue of post-translational modiﬁcation that can drive
activation. For example, in healthy cells Bad is phosphorylated on
serine residues leading to its sequestration in the cytosol through
interactions with 14–3–3 scaffold proteins. The function of Bad can
also be controlled on themitochondria. In healthy liver cells, a portion
of Bad resides in a functional holoenzyme complex on mitochondria
that includes Protein Kinase A, Protein Phosphatase 1, WAVE-1 as an
A-kinase anchoring protein (AKAP) and glucokinase [21,91]. This
protein scaffold allows PKA to speciﬁcally phosphorylate Bad on
serine 122 following IL-3 induction [21]. In addition, in PC12 cells, the
AKAP protein AKAP121 targets PKA to the mitochondria, which
stimulates BAD phosphorylation on serine 155 [92]. Disruption of this
scaffold impairs BAD phosphorylation and sensitizes cells to apoptosis
even in the presence of survival factors [21,92]. Bad can also be
cleaved by caspases following apoptotic stimuli [93–95]. Bad lacking
the N-terminal region has a higher afﬁnity for the OMM and Bcl-XL
and is a more potent inducer of apoptosis. This is analogous to Bid,
which translocates to the mitochondria and is more active following
caspase cleavage [87,96,97]. One could speculate that these proteins
contain an N-terminal inhibitory domain, that when released allows
the protein to interact with a mitochondrial receptor.
5. Conclusions and perspectives
An essential part of the role of Bcl-2 family proteins is that they are
directed to the correct intracellular membranes. Although recent
work on these apoptosis regulators has provided much data on the
interaction between family members, our knowledge of how they
correctly target to mitochondria is still fragmentary. Given that the
molecular mechanisms for correct mitochondrial targeting are likely
to be central to the proper regulation of this important protein family,
an understanding of this process and the interactions required is
essential. This review has outlined the various interactions that may
drive the targeting of Bcl-2 proteins to mitochondria and their
subsequent activity in apoptosis. Better understanding of these
targeting mechanisms is important if we are to clarify how apoptosis
is regulated.
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